FIELD: medicine.
SUBSTANCE: for treatment of circadian rhythm violations, the patient suffering from "non-24" syndrome receives 20 mg of tazimelteone orally once in a day, before the required bedtime.
EFFECT: biological clock adjustment to the 24-hour sleep-wake cycle.
9 cl, 17 dwg, 10 tbl
Title | Year | Author | Number |
---|---|---|---|
TREATMENT OF CIRCADIAN RHYTHM DISORDERS | 2013 |
|
RU2650647C2 |
TREATMENT OF CIRCADIAN RHYTHM DISORDERS | 2013 |
|
RU2748386C2 |
WAY TO IMPROVE SLEEP | 2020 |
|
RU2804441C2 |
METABOLITES (1R-TRANS)-N-[[2-(2,3-DIGIDRO-4-BENZOFURANYL)CYCLOPROPYL]-METHYL]PROPANAMIDE | 2013 |
|
RU2632889C2 |
AGENT FOR TREATMENT OF DESYNCHRONIZATION TROUBLES, AND PHARMACEUTICAL COMPOSITION | 1994 |
|
RU2160101C2 |
METHOD OF TREATMENT OF PATHOLOGICAL DEVIATIONS AT DIABETES MELLITUS OF TYPE-2 | 1992 |
|
RU2104698C1 |
MELATONIN AGONIST THERAPY | 2007 |
|
RU2488392C2 |
DIAGNOSTIC TECHNIQUE FOR CLINICALLY LATENT HYPERCORTICOIDISM IN PATIENTS SUFFERING FROM STYPE 2 DIABETES MELLITUS OR OBESITY | 2012 |
|
RU2521387C1 |
METHOD FOR NORMALISING INDIVIDUAL'S DIURNAL RHYTHM | 2013 |
|
RU2533965C1 |
METHOD FOR TREATING AND PREVENTING BENZODIAZEPINE GROUP MEDICAMENT ADDICTION OR INSENSITIVITY OR TOLERATION SYMPTOMS | 1996 |
|
RU2182001C2 |
Authors
Dates
2017-09-25—Published
2013-01-25—Filed